- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06788990
FORTIFI-HN01: Een fase 2/3-studie van Ficerafusp Alfa (BCA101) of Placebo in combinatie met Pembrolizumab in eerstelijns PD-L1-pos, R of M HNSCC (FORTIFI-HN01)
Een multicenter, gerandomiseerde, dubbelblinde fase 2/3-studie van Ficerafusp Alfa (BCA101) of Placebo in combinatie met Pembrolizumab voor eerstelijnsbehandeling van PD-L1-positief, recidiverend of gemetastaseerd plaveiselcelcarcinoom van hoofd en nek
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β).
This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The mechanism of action of ficerafusp alfa involves dual targeting of two cancer targets, EGFR and TGF-β, which are known to drive solid tumor growth and metastasis.
Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:
- Arm A: ficerafusp alfa 1500 mg once weekly (QW) + pembrolizumab 200 mg every three weeks (Q3W).
- Arm B: ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W.
- Arm C (control): placebo QW + pembrolizumab 200 mg Q3W.
The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab. Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Medical Affairs
- Telefoonnummer: 1-617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
Studie Locaties
-
-
-
Buenos Aires, Argentinië, C1190
- Werving
- CEMIC (Site # 2301)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Buenos Aires, Argentinië, C1425
- Werving
- ICM Center (Site # 2306)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Pilar, Argentinië, B1629ODT
- Werving
- Hospital Universitario Austral (Site # 2303)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rosario, Argentinië, CP2000
- Werving
- Sanatorio de la Mujer (Site # 2305)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Santa Fe, Argentinië, S2002KDT
- Werving
- Hospital Provincial del Centenario (Site # 2302)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
New South Wales
-
Camperdown, New South Wales, Australië, 2050
- Werving
- Chris O'Brien Lifehouse (Site#0302)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Kingswood, New South Wales, Australië, 2747
- Werving
- Nepean Hospital (Site #0306)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Waratah, New South Wales, Australië, 2298
- Werving
- Calvary Mater Newcastle (Site#0304)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Queensland
-
Southport, Queensland, Australië, 4215
- Werving
- Gold Coast University Hospital (Site #0305)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Tugun, Queensland, Australië, 4224
- Werving
- John Flynn Private Hospital (Site#0307)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Victoria
-
Heidelberg, Victoria, Australië, 3084
- Werving
- Austin Health (Site #0303)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
North Melbourne, Victoria, Australië, 3051
- Werving
- Peter Macallum Cancer Centre (Site#0301)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Western Australia
-
Murdoch, Western Australia, Australië, 6150
- Werving
- Fiona Stanley Hospital (Site#0308)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Bruges, België, 8000
- Werving
- AZ St-Jan Brugge Oostende av (Campus Sint-Jan) (Site #1007)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Mons, België, 7000
- Werving
- CHU Ambroise Paré (Site #1005)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Namur, België, 5000
- Werving
- CHU UCL Namur, Site Ste. Elisabeth (Site #1002)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Namur, België, 5530
- Werving
- CHU UCL Namur, Site Mont-Godinne (Site #1003)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Sint-Niklaas, België, 9100
- Werving
- Vitaz (Site #1001)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Wilrijk, België, 2610
- Werving
- ZAS Augustinus (Site #1006)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Barretos, Brazilië, 14784-400
- Werving
- Hospital de Amor de Barretos - Fundação Pio XII (Site # 2413)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Belém, Brazilië, 66063495
- Werving
- Centro de Tratamento Oncologico (Site # 2421)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Curitiba, Brazilië, 80810-050
- Werving
- CIONC-Centro Integrado de Oncologia de Curitiba (Site # 2404)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Fortaleza, Brazilië, 60430235
- Werving
- Hospital Haroldo Juaçaba - Instituto do Câncer do Ceará (Site # 2414)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Ijuí, Brazilië, 98700-000
- Werving
- Oncosite - Centro de Pesquisa Clinica e Oncologia (Site # 2402)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Jaú, Brazilië, 17210-120
- Werving
- Fundação Doutor Amaral Carvalho (Site # 2411)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Natal, Brazilië, 59062-000
- Werving
- Liga Norte-Rio-Grandense Contra o Câncer (Site # 2422)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Passo Fundo, Brazilië, 99010-260
- Werving
- Hospital de Clínicas de Passo Fundo (Site # 2419)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Porto Alegre, Brazilië, 91350-200
- Werving
- Hospital Nossa Senhora da Conceicao (Site # 2403)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rio de Janeiro, Brazilië, 22250-905
- Werving
- Grupo Oncoclínicas (Site # 2412)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Santa Cruz do Sul, Brazilië, 96835-100
- Werving
- Hospital Ana Nery (Site # 2415)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Santa Lúcia, Brazilië, 30360680
- Werving
- Oncoclinicas do Brasil Serviços Médicos S.A - Oncocentro BH (Site # 2401)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
São Caetano do Sul, Brazilië, 09541-270
- Werving
- Centro de Oncologia do ABC - Unidade Santo Andre (Site # 2410)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
São José do Rio Preto, Brazilië, 15090-000
- Werving
- Centro Integrado de Pesquisa do Hospital de Base de São José do Rio Preto/FUNFAR (Site # 2406)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brazilië, 01246-000
- Werving
- Instituto do Cancer do Estado de Sao Paulo (ICESP) (Site # 2417)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brazilië, 01509-900
- Werving
- A. C. Camargo Cancer Center (Site # 2409)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brazilië, 04014-002
- Werving
- IBCC Núcleo de Pesquisa e Ensino (Site # 2405)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brazilië, 04543
- Werving
- Oncoclínicas - SP (Site # 2416)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
São Paulo, Brazilië, 08270-120
- Werving
- Hospital Santa Marcelina (Site # 2418)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Vitoria ES
-
Santa Cecília, Vitoria ES, Brazilië, 29043-260
- Werving
- AFECC Hospital Santa Rita de Cassia (Site # 2420)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Toronto, Canada, M4N 3M5
- Werving
- Sunnybrook Health Sciences Centre (Site # 0204)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Werving
- BC Cancer - Vancouver (Site #0202)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0C1
- Werving
- Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame (Site #0203)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Aachen, Duitsland, 52074
- Werving
- Universitaetsklinikum Aachen AOeR (Site #0710)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Berlin, Duitsland, 12200
- Werving
- Charite - Campus Benjamin Franklin (Site # 0701)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Berlin, Duitsland, 12351
- Werving
- Vivantes Klinikum Neukoelln (Site # 0714)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Braunschweig, Duitsland, 38114
- Werving
- Staedtisches Klinikum Braunschweig gGmbH (Site # 0709)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Chemnitz, Duitsland, 09116
- Werving
- Klinikum Chemnitz gGmbH (Site # 0705)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Dresden, Duitsland, 01067
- Werving
- Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt (Site #0707)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Dresden, Duitsland, 01307
- Werving
- Universitaetsklinikum Carl Gustav Carus TU Dresden (Site # 0711)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Düsseldorf, Duitsland, 40225
- Werving
- Heinrich-Heine-Universitaet Duesseldorf (Site #0706)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Essen, Duitsland, 45147
- Werving
- Universitaetsklinikum Essen (Site # 0716)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Göttingen, Duitsland, 37075
- Werving
- Universitaetsmedizin Goettingen (Site # 0708)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Hanover, Duitsland, 30625
- Werving
- Medizinische Hochschule Hannover (Site # 0718)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Karlsruhe, Duitsland, 76137
- Werving
- Vincentius-Diakonissen-Kliniken gAG/St. Vincentius-Kliniken (Site #0717)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
München, Duitsland, 81675
- Werving
- Technische Universität München School of Medicine (Site # 0715)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Stuttgart, Duitsland, 70174
- Werving
- Klinikum Stuttgart-Katharinenhospital (Site # 0703)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Ulm, Duitsland, 89075
- Werving
- Universitaetsklinikum Ulm (Site # 0702)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Amiens, Frankrijk, 80480
- Werving
- CHU Amiens - Hopital Sud (Site #0809)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Bordeaux, Frankrijk, 33075
- Werving
- CHU de Bordeaux (Site # 0812)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Lille, Frankrijk, 59000
- Werving
- Centre Oscar Lambret (Site # 0804)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Lyon, Frankrijk, 69004
- Werving
- Centre Hospitalier de la Croix Rousse (Site #0810)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Paris, Frankrijk, 75005
- Werving
- Institut Curie - site de Paris (Site # 0813)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rennes, Frankrijk, 35042
- Werving
- CRLCC Eugene Marquis (Site #0805)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Saint-Grégoire, Frankrijk, 35760
- Werving
- Les Hopitaux Prives Rennais - Saint-Gregoire (Site #0807)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Strasbourg, Frankrijk, 67200
- Werving
- Centre Regional Lutte Contre Le Cancer - PAUL STRAUSS (Site #0808)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Toulouse, Frankrijk, 31059
- Werving
- IUCT-Oncopole (Site # 0811)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Vandœuvre-lès-Nancy, Frankrijk, 54519
- Werving
- ICL - Alexis Vautrin (Site #0806)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Villejuif, Frankrijk, 94805
- Werving
- Institut Gustave Roussy (Site #0801)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Athens, Griekenland, 12461
- Werving
- U.G.H. ATTIKON - General Hospital of West Attica "H AGIA VARVARA" (Site # 1701)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Larissa, Griekenland, 41110
- Werving
- University General Hospital of Larissa (Site # 1702)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Cork, Ierland, T12 DC4A
- Werving
- Cork University Hospital - Consultants Private Clinic (Site # 0603)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Dublin, Ierland, D08 NHY1
- Werving
- Trinity College Dublin (TCD) - St. James's Hospital (SJH) (Site #0602)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Dublin, Ierland, D09 V2N0
- Werving
- Beaumont Hospital (Site #0601)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Madurai, Indië, 625107
- Werving
- Meenakshi Mission Hospital & Research Centre (Site # 3003)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Sūrat, Indië, 395004
- Werving
- Nirmal Hospital (Site # 3002)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Beersheba, Israël, 84101
- Werving
- Soroka Medical Center (Site # 1901)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Jerusalem, Israël, 9112001
- Werving
- Hadassah Medical Center (Site # 1903)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Petah Tikva, Israël, 49100
- Werving
- Rabin Medical Center (Site # 1904)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Tel Aviv, Israël, 6423906
- Werving
- Sourasky Medical Center (Site # 1902)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Bologna, Italië, 40138
- Werving
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi (Site #0904)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Cagliari, Italië, 09121
- Werving
- ARNAS G. Brotzu (Site # 913)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Florence, Italië, 50134
- Werving
- Azienda Ospedaliera Universitaria Careggi (Site #0911)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Milan, Italië, 20132
- Werving
- Ospedale San Raffaele (Site #0907)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Milan, Italië, 20133
- Werving
- Fondazione IRCCS Istituto Nazionale dei Tumori (Site #0901)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Milan, Italië, 20142
- Werving
- ASST Santi Paolo e Carlo, Ospedale San Paolo Polo Universitario (Site #0905)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Milan, Italië, 20162
- Werving
- Azienda Socio Sanitaria Territoriale Niguarda (Site # 0912)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Naples, Italië, 80131
- Werving
- Istituto Nazionale Tumori Fondazione G. Pascale (Site #0915)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Naples, Italië, 80131
- Werving
- UOC Oncoematologia AOU - University Luigi Vanvitelli (Site # 0916)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Padova, Italië, 35128
- Werving
- IOV - Istituto Oncologico Veneto IRCCS (Site # 0910)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Palermo, Italië, 90127
- Werving
- Policlinico P. Giaccone di Palermo (Site #0908)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Pavia, Italië, 27100
- Werving
- Fondazione IRCCS Policlinico San Matteo (Site # 0903)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Pisa, Italië, 56126
- Werving
- Azienda Ospedaliero Universitaria Pisana (Site # 0909)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rome, Italië, 00161
- Werving
- Azienda Ospedaliero-Universitaria Policlinico Umberto I (Site #0917)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rome, Italië, 00168
- Werving
- Fondazione Policlinico Universitario - Agostino Gemelli (Site #0918)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rome, Italië, 00186
- Werving
- Fatebenefratelli Isola Tiberina, Gemelli Isola (Site #0906)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rozzano, Italië, 20089
- Werving
- Humanitas Mirasole S.p.A (Site # 0919)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Siena, Italië, 53100
- Werving
- A.O.U. Senese Policlinico Santa Maria alle Scotte (Site # 0902)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Kōtoku, Japan, 135-8550
- Werving
- Cancer Institute Hospital of JFCR (Site # 3107)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
George Town, Maleisië, 11200
- Werving
- Mount Miriam Cancer Hospital (Site # 2802)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Kuala Lumpur, Maleisië, 50586
- Werving
- Hospital Kuala Lumpur (Site # 2803)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Kuala Lumpur, Maleisië, 59100
- Werving
- University Malaya Medical centre (Site # 2805)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Kuching, Maleisië, 93200
- Werving
- Sarawak General Hospital (Site # 2801)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Pulau Pinang, Maleisië, 10450
- Werving
- Hospital Pulau Pinang (Site # 2804)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Christchurch, Nieuw-Zeeland, 8011
- Werving
- Christchurch Hospital NZ (Site #0401)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rotorua, Nieuw-Zeeland, 3010
- Werving
- Rotorua Hospital (Site#0402)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Salzburg, Oostenrijk, 5020
- Werving
- Hematology and Medical Oncology, Paracelsus Medical University (Site #1602)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Vienna, Oostenrijk, 1090
- Werving
- Medical University Vienna (Site #1601)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Gdansk, Polen, 80-214
- Werving
- UNIWERSYTECKIE CENTRUM KLINICZNE (Site #1401)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Gliwice, Polen, 44-102
- Werving
- Centrum Onkologii-Instytut im.M.Sklodowskiej Curie (Site # 1405)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Katowice, Polen, 40-519
- Werving
- Pratia Onkologia Katowice (Site #1403)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Konin, Polen, 62-500
- Werving
- Przychodnia Lekarska Komed (Site #1407)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Krakow, Polen, 31-826
- Werving
- Szpital Specjalistyczny im. L.Rydygiera w Krakowie (Site #1404)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Siedlce, Polen, 08-110
- Werving
- Mazowiecki Szpital Wojewódzki im. sw. Jana Pawla II w Siedlcach Sp. z o.o. (Site #1402)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Warsaw, Polen, 02-781
- Werving
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curiee - Panstwowy Instytut (Site #1406)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Braga, Portugal, 4710-243
- Werving
- Centro Clínico Académico de Braga (Site #1506)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Coimbra, Portugal
- Werving
- Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE (Site #1503)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Lisbon, Portugal, 1099-023
- Werving
- Instituto Português de Oncologia Lisboa (Site #1508)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Portimão, Portugal, 8500-338
- Werving
- Centro Hospitalar Algarve (Site #1501)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Porto, Portugal, 4200-072
- Werving
- Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (Site #1505)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Porto, Portugal, 4200-319
- Werving
- Centro Hospitalar Universitario de Sao Joao (Site #1507)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Senhora da Hora, Portugal, 4464-509
- Werving
- Unidade Local de Saude de Matosinhos, E.P.E. - Hospital Pedro Hispano (Site #1502)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Vila Nova de Gaia, Portugal, 4434-502
- Werving
- Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E. (Site # 1504)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Novena, Singapore, 308433
- Werving
- Tan Tock Seng Hospital (Site # 2902)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Singapore, Singapore, 168583
- Werving
- National Cancer Centre Singapore (Site # 2901)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Badalona, Spanje, 8916
- Werving
- ICO Badalona - Hospital Universitari Germans Trias i Pujol (Site # 1311)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Barcelona, Spanje, 08035
- Werving
- Hospital Universitari Vall d'Hebron (Site #1301)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Barcelona, Spanje, 08036
- Werving
- Hospital Clinic de Barcelona (Site #1305)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Barcelona, Spanje, 08041
- Werving
- Hospital de la Santa Creu I Sant Pau Site #1304
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Barcelona, Spanje, 08908
- Werving
- Institut Catala d'Oncologia (Site # 1302)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Madrid, Spanje, 28027
- Werving
- Clinica Universidad de Navarra- Madrid (Site #1310)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Madrid, Spanje, 28041
- Werving
- Hospital Universitario 12 De Octubre (Site #1303)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Pamplona, Spanje, 31008
- Werving
- Clinica Universidad de Navarra (Site #1306)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Santander, Spanje, 39008
- Werving
- Hospital Universitario Marques de Valdecilla (HUMV) (Site #1309)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Valencia, Spanje, 46010
- Werving
- Hospital Clinico Universitario de Valencia (Site #1307)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Valencia, Spanje, 46014
- Werving
- Hospital General Universitario de Valencia (Site #1308)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Changhua, Taiwan, 50006
- Werving
- Changhua Christian Medical Foundation Changhua Christian Hospital (Site # 2602)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Kaohsiung City, Taiwan, 807
- Werving
- Kaohsiung Medical University Chung-Ho Memorial Hospital (Site # 2601)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-421
- E-mail: FORTIFI_inquiries@bicara.com
-
Taichung, Taiwan, 40447
- Werving
- China Medical University Hospital (CMUH) (Site # 2603)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Taipei, Taiwan, 10002
- Werving
- National Taiwan University Hospital (Site # 2604)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Bangkok, Thailand, 10400
- Werving
- Phramongkutklao Hospital (Site # 2505)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Bangkok, Thailand, 10400
- Werving
- Rajavithi Hospital (Site # 2504)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Chiang Mai, Thailand, 50200
- Werving
- Maharaj Nakorn Chiang Mai Hospital (Site # 2506)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Dusit, Thailand, 10300
- Werving
- Vajira Hospital (Site # 2503)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Hat Yai, Thailand, 90110
- Werving
- Songklanagarind Hospital (Site # 2502)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Hradec Králové, Tsjechië, 500 03
- Werving
- Fakultni Nemocnice Hradec Kralove (FNHK) (Site # 2101)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Prague, Tsjechië, 15006
- Werving
- Fakultni nemocnice Motol a Homolka (Site #2102)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Ankara, Turkije (Türkiye), 6100
- Werving
- Hacettepe University Medical Faculty (Site # 1201)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Ankara, Turkije (Türkiye), 6520
- Werving
- Memorial Ankara Hospital (Site # 1202)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Antalya, Turkije (Türkiye), 7020
- Werving
- Memorial Antalya Hastanesi (Site # 1204)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Istanbul, Turkije (Türkiye), 34098
- Werving
- Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty (Site # 1203)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Izmir, Turkije (Türkiye), 35330
- Werving
- Dokuz Eylul University Medical School (Site # 1206)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 2ZN
- Werving
- Aberdeen Royal Infirmary (Site #0504)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Birmingham, Verenigd Koninkrijk, B15 2TH
- Werving
- University Hospitals Birmingham (Queen Elizabeth Hospital) (Site #0512)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Cambridge, Verenigd Koninkrijk, CB2 0QQ
- Werving
- Cambridge University Hospitals (Site #0513)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Glasgow, Verenigd Koninkrijk, G12 0YN
- Werving
- Beatson West of Scotland Cancer Centre (Site # 0510)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Leeds, Verenigd Koninkrijk, LS9 7TF
- Werving
- St James University Hospital Leeds (Site #0511)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Liverpool, Verenigd Koninkrijk, L7 8YA
- Werving
- Clatterbridge Cancer Center NHS Foundation (Site #0507)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
London, Verenigd Koninkrijk, SW3 6JJ
- Werving
- Royal Marsden Hospital - Chelsea (Site #0505)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
London, Verenigd Koninkrijk, WC1E 6AG
- Werving
- University College London Hospital (Site #0502)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Manchester, Verenigd Koninkrijk, M20 4BX
- Werving
- The Christie Hospital (Site #0508)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Middlesex, Verenigd Koninkrijk, HA6 2RN
- Werving
- Mount Vernon Cancer Centre (Site #0506)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Newcastle upon Tyne, Verenigd Koninkrijk, NE7 7DN
- Werving
- Newcastle University (Site # 509)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Nottingham, Verenigd Koninkrijk, NG5 1PB
- Werving
- Nottingham University Hospitals City Campus (Site #0503)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Oxford, Verenigd Koninkrijk, OX3 7LE
- Werving
- Churchill Hospital (Site #0515)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Portsmouth, Verenigd Koninkrijk, PO6 3LY
- Werving
- Queen Alexandra Hospital (Site # 0514)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Sutton, Verenigd Koninkrijk, SM2 5PT
- Werving
- Royal Marsden Hospital- London (Site # 0501)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- Werving
- University of Alabama Hospital (Site # 0137)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Werving
- Mayo Clinic Hospital (Site #0147)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
California
-
La Jolla, California, Verenigde Staten, 92093
- Werving
- UC San Diego Moores Cancer Center (Site #0107)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Los Angeles, California, Verenigde Staten, 90095
- Werving
- UCLA Department of Medicine - Hematology/Oncology (Site #0106)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Sacramento, California, Verenigde Staten, 95817
- Werving
- UC Davis (Site#0144)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
San Francisco, California, Verenigde Staten, 94143
- Werving
- University of California San Francisco (Site #0130)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Stanford, California, Verenigde Staten, 94305
- Werving
- Stanford Cancer Institute (Site #0150)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80012
- Werving
- Rocky Mountain Cancer Centers, LLP (Site #0122)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- Rocky Mountain Regional VAMC (Site #0124)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Aurora, Colorado, Verenigde Staten, 80045
- Werving
- University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Delaware
-
Newark, Delaware, Verenigde Staten, 19713
- Werving
- ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224
- Werving
- Mayo Clinic Florida (Site #0148)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Palm Bay, Florida, Verenigde Staten, 32901
- Werving
- Cancer Care Centers of Brevard (Site #0136)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Tampa, Florida, Verenigde Staten, 33612
- Werving
- Moffit Cancer Center (Site #0105)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60064
- Werving
- Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- Werving
- University of Iowa Hospitals & Clinics (Site#0140)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Kansas
-
Westwood, Kansas, Verenigde Staten, 66205
- Werving
- University of Kansas Medical Center Research Institute, Inc. (Site #0149)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- Werving
- University of Kentucky, Markey Cancer Center (Site # 109)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- Norton Cancer Institute (Site#0111)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Louisville, Kentucky, Verenigde Staten, 40202
- Werving
- The University of Louisville, James Graham Brown Cancer Center (Site#0115)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21201
- Werving
- University of Maryland Medical Group (Site #0112)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Werving
- Massachusetts General Hospital (Site #0131)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Boston, Massachusetts, Verenigde Staten, 02136
- Werving
- Dana-Farber Cancer Institute (Site#0101)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- Werving
- University of Michigan (Site # 161)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Minnesota
-
Maplewood, Minnesota, Verenigde Staten, 55109
- Werving
- Site #0156
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Rochester, Minnesota, Verenigde Staten, 55905
- Werving
- Mayo Clinic Cancer Center - Rochester (Site #0146)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Washington University School of Medicine (Site #0114)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Werving
- Hackensack Meridian Health (Site # 119)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Newark, New Jersey, Verenigde Staten, 07103
- Werving
- Rutgers- Cancer Institute (Site #0145)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
New York
-
New York, New York, Verenigde Staten, 10003
- Werving
- Mount Sinai (Site #0155)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
New York, New York, Verenigde Staten, 10021
- Werving
- Memorial Sloan Kettering Cancer Center (Site#0142)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27703
- Werving
- Duke University Health System (Site#0118)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Ohio
-
Canton, Ohio, Verenigde Staten, 44708
- Werving
- Mercy Hospital (Site#0154)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Cincinnati, Ohio, Verenigde Staten, 45221
- Werving
- University of Cincinnati Cancer Institute (Site#0117)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Cleveland, Ohio, Verenigde Staten, 44106
- Werving
- University Hospitals Seidman Cancer Center (Site #0151)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Cleveland, Ohio, Verenigde Staten, 44195
- Werving
- Cleveland Clinic (Site #0108)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97213
- Werving
- Providence Portland Medical Center (Site #0113)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15206
- Werving
- UPMC Hillman Cancer Center (Site #0103)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15240
- Werving
- VA Pittsburgh Healthcare System (Site #0123)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02903
- Werving
- Lifespan Cancer Institute (Site #0132)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina (MUSC) (Site#0104)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- SCRI-Oncology Partners (Site#0126)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Nashville, Tennessee, Verenigde Staten, 37232
- Werving
- Vanderbilt-Ingram Cancer Center (Site #0116)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77005
- Werving
- MD Anderson Cancer Center (Site#0102)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Waco, Texas, Verenigde Staten, 676712
- Werving
- SCRI- Texas Oncology- Central South (Site #0152)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22904
- Werving
- University of Virginia (Site#0134)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Richmond, Virginia, Verenigde Staten, 23219
- Werving
- Virginia Commonwealth University (VCU) Massey Cancer Center (Site #0129)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Richmond, Virginia, Verenigde Staten, 23249
- Werving
- Richmond Department of Veterans Affairs (Site #0138)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Washington
-
Edmonds, Washington, Verenigde Staten, 98026
- Werving
- Swedish Cancer Institute - North Campus Edmonds (Site # 0160)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Seattle, Washington, Verenigde Staten, 98104
- Werving
- Swedish Cancer Institute (Site # 0159)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Seattle, Washington, Verenigde Staten, 98109
- Werving
- University of Washington - Seattle Cancer Care Alliance (Site #0125)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Vancouver, Washington, Verenigde Staten, 98684
- Werving
- Northwest Cancer Specialists, PC (Site#0120)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53705
- Werving
- William S. Middleton Memorial Veteran's Hospital (Site #0141)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Madison, Wisconsin, Verenigde Staten, 53792
- Werving
- University of Wisconsin Hospital and Clinics (Site #0157)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Milwaukee, Wisconsin, Verenigde Staten, 53233
- Werving
- Advocate Aurora Research Institute (Site # 0153)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Busan, Zuid -Korea, 49267
- Werving
- Kosin University Gospel Hospital (Site # 2707)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Goyang-si, Zuid -Korea, 10408
- Werving
- National Cancer Center (Site # 2704)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Hwasun, Zuid -Korea, 58128
- Werving
- Chonnam National University Hwasun Hospital (Site # 2705)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Seongnam, Zuid -Korea, 13620
- Werving
- Seoul National University Bundang Hospital (Site # 2706)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Seoul, Zuid -Korea, 3080
- Werving
- Seoul National University Hospital (Site # 2701)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Seoul, Zuid -Korea, 3722
- Werving
- SEVERANCE HOSPITAL, YONSEI UNIVERSITY (Site # 2702)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Seoul, Zuid -Korea, 6351
- Werving
- Samsung Medical Center (Site # 2703)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
-
-
-
Fribourg, Zwitserland, 1752
- Werving
- HFR Fribourg Kantonsspital Fribourg (Site # 1803)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Geneva, Zwitserland, 1205
- Werving
- Hopitaux Universitaires de Geneve (Site # 1802)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
Lausanne, Zwitserland, 1011
- Werving
- Centre Hospitalier Universitaire Vaudois (CHUV) (Site # 1801)
-
Contact:
- Principal Investigator
- Telefoonnummer: 617-468-4219
- E-mail: FORTIFI_inquiries@bicara.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥18 years on the day the Informed Consent Form is signed.
- Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.
- No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.
- Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.
- PD-L1 CPS ≥1.
- Measurable disease based on RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function, as defined in the protocol.
Exclusion Criteria:
- Disease suitable for local therapy administered with curative intent.
- Prior treatment with anti-TGFβ therapy.
- Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).
- Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.
- Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.
- Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.
- Life expectancy less than 3 months.
- Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.
- Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.
- Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.
- Active autoimmune disease requiring systemic treatment in the past 2 years.
- Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.
- Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.
- Known history of human immunodeficiency virus (HIV).
- Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.
- Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.
- Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.
- Use of a live or live attenuated vaccine within 4 weeks prior to Screening.
Other Inclusion/Exclusion criteria may apply as defined in the protocol.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Phase 2 Arm A
ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W) |
Investigational Immunotherapy agent used in combination with investigational agent |
|
Experimenteel: Phase 2 Arm B
ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W |
Investigational Immunotherapy agent used in combination with investigational agent |
|
Placebo-vergelijker: Phase 2 Arm C
placebo QW + pembrolizumab 200 mg Q3W |
Immunotherapy agent used in combination with investigational agent Placebo Control |
|
Experimenteel: Phase 3 OBD Arm
ficerafusp alfa OBD + pembrolizumab 200 mg Q3W |
Investigational Immunotherapy agent used in combination with investigational agent |
|
Placebo-vergelijker: Phase 3 Arm C
placebo QW + pembrolizumab 200 mg Q3W |
Immunotherapy agent used in combination with investigational agent Placebo Control |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Tijdsspanne: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
|
To assess safety and tolerability of ficerafusp alfa with pembrolizumab. |
Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
|
|
Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)
Tijdsspanne: Approximately 1 year.
|
ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR. |
Approximately 1 year.
|
|
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 2 years.
|
ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR. |
Approximately 2 years.
|
|
Phase 3 - Overall Survival (OS)
Tijdsspanne: Approximately 3 years.
|
OS: Defined as the time from the randomization to death due to any cause. |
Approximately 3 years.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 1 year.
|
DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first, per RECIST 1.1 by BICR. |
Approximately 1 year.
|
|
Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Tijdsspanne: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
|
To assess safety and tolerability of ficerafusp alfa with pembrolizumab. |
Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
|
|
Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 3 years.
|
PFS: Defined as the time from randomization to the first documented PD per RECIST 1.1 as determined by BICR or death due to any cause, whichever occurs first. |
Approximately 3 years.
|
|
Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 3 years.
|
ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS). |
Approximately 3 years.
|
|
Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 3 years.
|
DOR: For subjects who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first per RECIST 1.1 by BICR. |
Approximately 3 years.
|
|
Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.
Tijdsspanne: Approximately 3 years.
|
Clinical Benefit Rate: For subject who demonstrated CR + PR + SD>6 months per RECIST 1.1 by BICR. |
Approximately 3 years.
|
|
Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.
Tijdsspanne: Approximately 3 years.
|
ORR, per RECIST 1.1 as determined by investigator's assessment. |
Approximately 3 years.
|
|
Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.
Tijdsspanne: Approximately 3 years.
|
DOR, per RECIST 1.1 as determined by investigator's assessment. |
Approximately 3 years.
|
|
Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.
Tijdsspanne: Approximately 3 years.
|
PFS, per RECIST 1.1 as determined by investigator's assessment. |
Approximately 3 years.
|
|
Phase 3 - 14. Time to deterioration (TTD) in global health status measured by the EORTC QLQ C30 items for global health status and quality of life scale (item 29/30)
Tijdsspanne: Approximately 3 years.
|
To evaluate TTD in global health status/quality of life in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab. TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher value indicates a better level of function. |
Approximately 3 years.
|
|
Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.
Tijdsspanne: Approximately 3 years.
|
To evaluate TTD in pain in subjects treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab. TTD defined as the time from first dose (baseline) to change in pain score by 10-point from baseline, using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core Head and Neck Module (EORTC HN35). A higher score indicates a higher level of symptom burden. |
Approximately 3 years.
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Botziekten
- Musculoskeletale aandoeningen
- Neoplasmata per site
- Neoplasmata
- Genetische ziekten, aangeboren
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Carcinoom
- KNO-ziekten
- Carcinoom, plaveiselcel
- Osteochondrodysplasie
- Botziekten, ontwikkelingsstoornissen
- Aangeboren, erfelijke en neonatale ziekten en afwijkingen
- Plaveiselcelcarcinoom van hoofd en hals
- Hoofd- en nekneoplasmata
- Laryngeale ziekten
- Camurati-Engelmann-syndroom
- pembrolizumab
Andere studie-ID-nummers
- BCA101X301
- 2024-519654-37-00 (Ctis)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .